# Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors

> **NCT00259818** · PHASE1 · COMPLETED · sponsor: **Erimos Pharmaceuticals** · enrollment: 30 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** EM-1421

## Key facts

- **NCT ID:** NCT00259818
- **Lead sponsor:** Erimos Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** —
- **Final completion:** 2008-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2008-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00259818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00259818, "Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00259818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*